Klompas Allan M, Albright Robert C, Maltais Simon, Demirci Onur
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Department of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Ann Card Anaesth. 2019 Apr-Jun;22(2):204-206. doi: 10.4103/aca.ACA_114_18.
Heparin-induced thrombocytopenia type II is a rare but devastating complication of heparin exposure. We review a case of a 66-year-old female who underwent aortic valve surgery requiring venoarterial extracorporeal membranous oxygenation (ECMO) support postoperatively. She subsequently developed acute renal failure due to bilateral renal vein thromboses and thrombocytopenia and was found to have platelet factor 4/heparin antibodies and was diagnosed with heparin-induced thrombocytopenia (HIT). She was transitioned to nonheparin anticoagulation and her thrombocytopenia improved. Although a rare complication of anticoagulation, diagnosing HIT in a patient on ECMO requires a high index of suspicion and should be considered.
II型肝素诱导的血小板减少症是肝素暴露后一种罕见但具有毁灭性的并发症。我们回顾了一例66岁女性患者的病例,该患者接受了主动脉瓣手术,术后需要静脉-动脉体外膜肺氧合(ECMO)支持。她随后因双侧肾静脉血栓形成和血小板减少症而发生急性肾衰竭,并被发现存在血小板因子4/肝素抗体,被诊断为肝素诱导的血小板减少症(HIT)。她改用非肝素抗凝治疗,血小板减少症得到改善。尽管抗凝治疗的这种并发症很罕见,但在接受ECMO治疗的患者中诊断HIT需要高度怀疑,应予以考虑。